

GENITOURINÁRIO - Moderador - Dr. Augusto Motta

HORA	ABSTRACT	NÚMERO	PALESTRANTE
18:30 - 19:00	Simpósio Satélite - Janssen Atualizações no Câncer de Próstata 2021 – Novidades ASCO		Dr. Andre Poisl Fay e Dr. Diogo Assed Bastos
19:00 - 20:00	Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257	4503	Dr. André Fay
	Pembrolizumab versus placebo as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase 3 KEYNOTE-564 study	LBA5	Dr. André Fay
	Phase 3 study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION)	LBA4	Dr. Diogo Assed Bastos
	A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with de novo metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1	5000	Dr. Diogo Assed Bastos
	Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)	4502	Dr. Benedito Carneiro
	Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes	5004	Dr. Benedito Carneiro
20:00 - 20:30	Simpósio Satélite - Pfizer Atualização em Carcinomas Geniturinário		Dr. Andrey Soares

CÂNCER DE PELE E SARCOMAS - Moderador - Dr. Antônio Buzaid

HORA	ABSTRACT	NÚMERO	PALESTRANTE
20:30 - 21:15	Relatlimab (RELA) + nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase 3 results from RELATIVITY-047 (CA224-047)	9503	Dr. Jose Lutzky
	Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy	9505	Dr. Jose Lutzky
	CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma	9506	Dra. Andreia Melo
	Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma	9502	Dra. Andreia Melo
	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.	9500	Dr. Rodrigo Munhoz
	SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma	11504	Dr. Rodrigo Munhoz
	High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes	11520	Dr. Rodrigo Munhoz
21:15 - 21:45	Simpósio Satélite - Sanofi Câncer de pele não melanoma na ASCO 2021		Dr. Rafael Schmerling

CABEÇA E PESCOÇO/NEURO - Moderador - Dr. William William

HORA	ABSTRACT	NÚMERO	PALESTRANTE
21:45 - 22:30	Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas	2000	Dr. Olavo Feher
	Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.	2002	Dr. Olavo Feher
	Long-term results of the GEINO 140 TRIAL: randomizing patients to stop or to continue temozolomide until 12 cycles	2013	Dr. Olavo Feher
	Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase III trial	6000	Dra. Aline Lauda
	JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)	LBA2	Dra. Aline Lauda
	Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial	6003	Dr. Pedro de Marchi
	Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial	6001	Dr. Pedro de Marchi

APOIO INSTITUCIONAL



REALIZAÇÃO



COMERCIALIZAÇÃO



MAMA - Moderador - Dr. Gustavo Werutsky

HORA	ABSTRACT	NÚMERO	PALESTRANTE
19:00 - 20:15	Olympia: A phase 3, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer	LBA1	Dr. Carlos Barrios
	A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EAI131	605	Dr. Carlos Barrios
	De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results	503	Dr. José Bines
	Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial	1003	Dr. José Bines
	Breast Cancer Index (BCI) and Prediction of Benefit from Extended Aromatase Inhibitor (AI) Therapy (tx) in HR+ Breast Cancer: NRG Oncology/NSABP B-42.	501	Dr. Rafael Kaliks
	Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study	1002	Dr. Rafael Kaliks

GINECOLOGIA - Moderador - Dr. Fernando Maluf

HORA	ABSTRACT	NÚMERO	PALESTRANTE
20:15 - 21:15	Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890)	5501	Dra. Angelica Nogueira
	Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial	5502	Dra. Angelica Nogueira
	Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708)	5506	Dra. Andrea Gadelha
	Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis	5504	Dra. Andrea Gadelha
	Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase 3 OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)	LBA3	Dra. Aknar Calabrich
21:15 - 21:45	Simpósio Satélite - Pfizer Dados de mundo real em câncer de mama metastático HR+ HER2-		Dra. Daniela Rosa

HEMATOLOGIA - Moderador - Dr. Philip Sheinberg

HORA	ABSTRACT	NÚMERO	PALESTRANTE
21:45 - 22:30	First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia	7500	Dr. Jorge Vaz Pinto Neto
	Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KcD) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM)	8000	Dr. Jorge Vaz Pinto Neto
	Myeloablative vs non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma CALGB 51101 (Alliance)	7506	Dr. Daniel Tabak
	Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2	8004	Dr. Daniel Tabak
	Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPCR5D) \times CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM)	8008	Dr. Luciano Costa
	Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1	8005	Dr. Luciano Costa

APOIO INSTITUCIONAL

REALIZAÇÃO

COMERCIALIZAÇÃO



GASTROINTESTINAL - Moderadora - Dra. Anelisa Coutinho

HORA	ABSTRACT	NÚMERO	PALESTRANTE
19:00 - 20:00	Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer	3500	Dra. Rachel Riechelmann
	Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY)	4006	Dra. Rachel Riechelmann
	The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer	3507	Dr. Caio Rocha Lima
	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01)	3505	Dr. Caio Rocha Lima
	Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577	4003	Dr. Gustavo Fernandes
	Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study	LBA4001	Dr. Gustavo Fernandes
20:00 - 20:30	Projeto CURA apresenta Prêmio Renata Thormann Prociány		

PULMÃO - Moderador - Dr. Luiz Henrique Araújo

HORA	ABSTRACT	NÚMERO	PALESTRANTE
20:30 - 21:30	IMpower010: Primary results of a phase III global study of atezolizumab vs. best supportive care after adjuvant chemotherapy in resected Stage IB-IIIa non-small cell lung cancer (NSCLC)	8500	Dra. Carolina Kawamura
	Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET)	8504	Dra. Carolina Kawamura
	Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.	8505	Dr. Vladimir Lima
	Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.	9002	Dr. Vladimir Lima
	First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.	9000	Dr. Daniel Costa
	Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.	9006	Dr. Daniel Costa